133 related articles for article (PubMed ID: 24092864)
41. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
Guedj J; Neumann AU
J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
[TBL] [Abstract][Full Text] [Related]
42. Is hepatitis C virus eradication around the corner only 25 years after its discovery?
Ippolito G; Capobianchi MR; Lanini S; Antonelli G
Int J Antimicrob Agents; 2015 Feb; 45(2):111-2. PubMed ID: 25249016
[TBL] [Abstract][Full Text] [Related]
43. Anti-Hepatitis C Virus Activity of a Crude Extract from Longan (Dimocarpus longan Lour.) Leaves.
Apriyanto DR; Aoki C; Hartati S; Hanafi M; Kardono LB; Arsianti A; Louisa M; Sudiro TM; Dewi BE; Sudarmono P; Soebandrio A; Hotta H
Jpn J Infect Dis; 2016 May; 69(3):213-20. PubMed ID: 26255732
[TBL] [Abstract][Full Text] [Related]
44. [Novel strategies for preventing viral hepatitis C recurrence after liver transplantation].
Stoll-Keller F; Fafi-Kremer S; Wolf P; Doffoël M; Baumert T
Bull Acad Natl Med; 2008 Nov; 192(8):1657-67; discussion 1667-8. PubMed ID: 19445379
[TBL] [Abstract][Full Text] [Related]
45. Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes.
Chamoun-Emanuelli AM; Pecheur EI; Simeon RL; Huang D; Cremer PS; Chen Z
Antimicrob Agents Chemother; 2013 Jun; 57(6):2571-81. PubMed ID: 23529728
[TBL] [Abstract][Full Text] [Related]
46. (4R,6S)-2-Dihydromenisdaurilide is a Butenolide that Efficiently Inhibits Hepatitis C Virus Entry.
Chung CY; Liu CH; Wang GH; Jassey A; Li CL; Chen L; Yen MH; Lin CC; Lin LT
Sci Rep; 2016 Jul; 6():29969. PubMed ID: 27426693
[TBL] [Abstract][Full Text] [Related]
47. Activity-based and fraction-guided analysis of Phyllanthus urinaria identifies loliolide as a potent inhibitor of hepatitis C virus entry.
Chung CY; Liu CH; Burnouf T; Wang GH; Chang SP; Jassey A; Tai CJ; Tai CJ; Huang CJ; Richardson CD; Yen MH; Lin CC; Lin LT
Antiviral Res; 2016 Jun; 130():58-68. PubMed ID: 27012176
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of hepatitis C virus infection by polyoxometalates.
Qi Y; Xiang Y; Wang J; Qi Y; Li J; Niu J; Zhong J
Antiviral Res; 2013 Nov; 100(2):392-8. PubMed ID: 24025401
[TBL] [Abstract][Full Text] [Related]
49. Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking.
Blaising J; Lévy PL; Gondeau C; Phelip C; Varbanov M; Teissier E; Ruggiero F; Polyak SJ; Oberlies NH; Ivanovic T; Boulant S; Pécheur EI
Cell Microbiol; 2013 Nov; 15(11):1866-82. PubMed ID: 23701235
[TBL] [Abstract][Full Text] [Related]
50. Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.
Colpitts CC; Tawar RG; Mailly L; Thumann C; Heydmann L; Durand SC; Xiao F; Robinet E; Pessaux P; Zeisel MB; Baumert TF
Gut; 2018 Apr; 67(4):736-745. PubMed ID: 28360099
[TBL] [Abstract][Full Text] [Related]
51. HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon.
Mutz P; Metz P; Lempp FA; Bender S; Qu B; Schöneweis K; Seitz S; Tu T; Restuccia A; Frankish J; Dächert C; Schusser B; Koschny R; Polychronidis G; Schemmer P; Hoffmann K; Baumert TF; Binder M; Urban S; Bartenschlager R
Gastroenterology; 2018 May; 154(6):1791-1804.e22. PubMed ID: 29410097
[TBL] [Abstract][Full Text] [Related]
52. Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds.
Tai CJ; Li CL; Tai CJ; Wang CK; Lin LT
J Vis Exp; 2015 Oct; (105):e53124. PubMed ID: 26555014
[TBL] [Abstract][Full Text] [Related]
53. Thromboxane A2 synthase inhibitors prevent production of infectious hepatitis C virus in mice with humanized livers.
Abe Y; Aly HH; Hiraga N; Imamura M; Wakita T; Shimotohno K; Chayama K; Hijikata M
Gastroenterology; 2013 Sep; 145(3):658-67.e11. PubMed ID: 23684750
[TBL] [Abstract][Full Text] [Related]
54. Procyanidin B1 purified from Cinnamomi cortex suppresses hepatitis C virus replication.
Li S; Kodama EN; Inoue Y; Tani H; Matsuura Y; Zhang J; Tanaka T; Hattori T
Antivir Chem Chemother; 2010 Aug; 20(6):239-48. PubMed ID: 20710064
[TBL] [Abstract][Full Text] [Related]
55. Identification of a Potent and Broad-Spectrum Hepatitis C Virus Fusion Inhibitory Peptide from the E2 Stem Domain.
Chi X; Niu Y; Cheng M; Liu X; Feng Y; Zheng F; Fan J; Li X; Jin Q; Zhong J; Li YP; Yang W
Sci Rep; 2016 Apr; 6():25224. PubMed ID: 27121372
[TBL] [Abstract][Full Text] [Related]
56. Dual blockade of hepatitis C virus entry at a gatekeeper of hepatocytes: Not only a preventive, but also therapeutic target of claudin 1.
Sugiyama M; Kanto T
Hepatology; 2016 Sep; 64(3):979-82. PubMed ID: 27405253
[No Abstract] [Full Text] [Related]
57. Benzhydrylpiperazine compounds inhibit cholesterol-dependent cellular entry of hepatitis C virus.
Chamoun-Emanuelli AM; Pécheur EI; Chen Z
Antiviral Res; 2014 Sep; 109():141-8. PubMed ID: 25019406
[TBL] [Abstract][Full Text] [Related]
58. Benzothiazepinecarboxamides: Novel hepatitis C virus inhibitors that interfere with viral entry and the generation of infectious virions.
Kim HY; Kong S; Oh S; Yang J; Jo E; Ko Y; Kim SH; Hwang JY; Song R; Windisch MP
Antiviral Res; 2016 May; 129():39-46. PubMed ID: 26850830
[TBL] [Abstract][Full Text] [Related]
59. HCV animal models and liver disease.
Vercauteren K; de Jong YP; Meuleman P
J Hepatol; 2014 Nov; 61(1 Suppl):S26-33. PubMed ID: 25443343
[TBL] [Abstract][Full Text] [Related]
60. A preliminary analysis of hepatitis C virus in pancreatic islet cells.
Blackard JT; Kong L; Lombardi A; Homann D; Hammerstad SS; Tomer Y
Virol J; 2017 Dec; 14(1):237. PubMed ID: 29258547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
